The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Personalizing therapy based on genomic features in patients with multiple myeloma
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, shares his perspectives on personalizing therapy in patients with multiple myeloma. According to Prof. Morgan, therapy choice should be based on high-risk or low-risk genetic factors in addition to the patient’s desires, performance status, and clinical status. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
